J. Ferlay, I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers et al., Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, vol.136, pp.359-386, 2015.

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, 2019. CA, Cancer J. Clin, vol.69, pp.7-34, 2019.

M. J. Haney, Y. Zhao, Y. S. Jin, S. M. Li, J. R. Bago et al., Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy, J. Neuroimmune Pharmacol, 2019.

T. F. Nishijima, A. M. Deal, G. R. Williams, H. K. Sanoff, K. A. Nyrop et al., Chemotherapy Toxicity Risk Score for Treatment Decisions in Older Adults with Advanced Solid Tumors, Oncologist, vol.23, pp.573-579, 2018.

I. S. Park, H. J. Kim, Y. Jeong, W. Kim, and J. Kim, Differential abilities of Korean soybean varieties to biosynthesize glyceollins by biotic and abiotic elicitors, Food Sci. Biotechnol, vol.26, pp.255-261, 2017.

M. R. Lee, J. Y. Kim, J. Chun, S. Park, H. J. Kim et al., Induction of glyceollins by fungal infection in varieties of Korean soybean, J. Microbiol. Biotechnol, vol.20, pp.1226-1229, 2010.

H. J. Kim, J. Lim, W. Kim, and J. Kim, Soyabean glyceollins: Biological effects and relevance to human health, Proc. Nutr. Soc, vol.71, pp.166-174, 2012.

T. H. Pham, S. Lecomte, T. Efstathiou, F. Ferriere, and F. Pakdel, An Update on the Effects of Glyceollins on Human Health: Possible Anticancer Effects and Underlying Mechanisms, Nutrients, vol.11, 2019.
URL : https://hal.archives-ouvertes.fr/hal-01978725

S. F. Bamji and C. Corbitt, Glyceollins: Soybean phytoalexins that exhibit a wide range of health-promoting effects, J. Funct. Foods, vol.34, pp.98-105, 2017.

S. Lecomte, F. Chalmel, F. Ferriere, F. Percevault, N. Plu et al., Glyceollins trigger anti-proliferative effects through estradiol-dependent and independent pathways in breast cancer cells, Cell Commun. Signal, vol.15, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01560288

M. E. Burow, S. M. Boue, B. M. Collins-burow, L. I. Melnik, B. N. Duong et al., Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through estrogen receptor alpha and beta, J. Clin. Endocrinol. Metab, vol.86, pp.1750-1758, 2001.

M. C. Zimmermann, S. L. Tilghman, S. M. Boué, V. A. Salvo, S. Elliott et al., Glyceollin I, a novel antiestrogenic phytoalexin isolated from activated soy, J. Pharmacol. Exp. Ther, vol.332, pp.35-45, 2010.

V. A. Salvo, S. M. Boué, J. P. Fonseca, S. Elliott, C. Corbitt et al., Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesis, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res, vol.12, pp.7159-7164, 2006.

C. E. Wood, T. B. Clarkson, S. E. Appt, A. A. Franke, S. M. Boue et al., Effects of soybean glyceollins and estradiol in postmenopausal female monkeys, Nutr. Cancer, vol.56, pp.74-81, 2006.

M. R. Bratton, E. C. Martin, S. Elliott, L. V. Rhodes, B. M. Collins-burow et al., Glyceollin, a novel regulator of mTOR/p70S6 in estrogen receptor positive breast cancer, J. Steroid Biochem. Mol. Biol, vol.150, pp.17-23, 2015.

L. V. Rhodes, S. L. Tilghman, S. M. Boue, S. Wang, H. Khalili et al., Glyceollins as novel targeted therapeutic for the treatment of triple-negative breast cancer, Oncol. Lett, vol.3, pp.163-171, 2012.

S. H. Lee, J. Lee, M. H. Jung, and Y. M. Lee, Glyceollins, a novel class of soy phytoalexins, inhibit angiogenesis by blocking the VEGF and bFGF signaling pathways, Mol. Nutr. Food Res, vol.57, pp.225-234, 2013.

S. Lee, J. Jee, J. Bae, K. Liu, and Y. M. Lee, A group of novel HIF-1? inhibitors, glyceollins, blocks HIF-1? synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding, J. Cell Physiol, vol.230, pp.853-862, 2015.

J. Abel and T. Haarmann-stemmann, An introduction to the molecular basics of aryl hydrocarbon receptor biology, Biol. Chem, vol.391, pp.1235-1248, 2010.

A. Poland, E. Glover, A. S. Kende, and . Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase, J. Biol. Chem, vol.251, pp.4936-4946, 1976.

S. K. Kolluri, U. Jin, and S. Safe, Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target, Arch. Toxicol, vol.91, pp.2497-2513, 2017.

S. Safe, Y. Cheng, and U. Jin, The Aryl Hydrocarbon Receptor (AhR) as a Drug Target for Cancer Chemotherapy, Curr. Opin. Toxicol, vol.2, pp.24-29, 2017.

I. A. Murray, A. D. Patterson, and G. H. Perdew, Aryl hydrocarbon receptor ligands in cancer: Friend and foe, Nat. Rev. Cancer, vol.14, pp.801-814, 2014.

, Tissue Expression of AHR-Summary-The Human Protein Atlas, 2019.

S. Narasimhan, E. Stanford-zulick, O. Novikov, A. Parks, J. Schlezinger et al., Towards Resolving the Pro-and Anti-Tumor Effects of the Aryl Hydrocarbon Receptor, Int. J. Mol. Sci, vol.19, 1388.

C. Tsai, C. Li, Y. Cheng, C. Lee, P. Liao et al., The inhibition of lung cancer cell migration by AhR-regulated autophagy, Sci. Rep, 2017.

C. Tsai, C. Li, P. Liao, Y. Chang, Y. Cheng et al., Aza-PBHA, a potent histone deacetylase inhibitor, inhibits human gastric-cancer cell migration via PKC?-mediated AHR-HDAC interactions, Biochim. Biophys. Acta Mol. Cell Res, 1867.

A. Pandini, M. S. Denison, Y. Song, A. A. Soshilov, and L. Bonati, Structural and Functional Characterization of the Aryl Hydrocarbon Receptor Ligand Binding Domain by Homology Modeling and Mutational Analysis, Biochemistry, vol.46, pp.696-708, 2007.

Y. Xing, M. Nukaya, K. A. Satyshur, L. Jiang, V. Stanevich et al., Identification of the Ah-Receptor Structural Determinants for Ligand Preferences, Toxicol. Sci, vol.129, pp.86-97, 2012.

M. Salzano, A. Marabotti, L. Milanesi, and A. Facchiano, Human aryl-hydrocarbon receptor and its interaction with dioxin and physiological ligands investigated by molecular modelling and docking simulations, Biochem. Biophys. Res. Commun, vol.413, pp.176-181, 2011.

M. K. Rasmussen, P. Balaguer, B. Ekstrand, M. Daujat-chavanieu, S. Gerbal-chaloin et al., -Methylindole) Is a Partial Aryl Hydrocarbon Receptor Agonist and Induces CYP1A1/2 and CYP1B1 Expression in Primary Human Hepatocytes, PLoS ONE, vol.11, issue.3, 2016.

P. Gong, Z. Madak-erdogan, J. A. Flaws, D. J. Shapiro, J. A. Katzenellenbogen et al., Estrogen receptor-? and aryl hydrocarbon receptor involvement in the actions of botanical estrogens in target cells, Mol. Cell. Endocrinol, vol.437, pp.190-200, 2016.

S. Kress and W. F. Greenlee, Cell-specific regulation of human CYP1A1 and CYP1B1 genes, Cancer Res, vol.57, pp.1264-1269, 1997.

H. Hanieh, O. Mohafez, V. I. Hairul-islam, A. Alzahrani, M. Bani-ismail et al., Novel Aryl Hydrocarbon Receptor Agonist Suppresses Migration and Invasion of Breast Cancer Cells, PLoS ONE, vol.11, 2016.

U. Jin, S. Lee, C. Pfent, and S. Safe, The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis, BMC Cancer, vol.14, 2014.

K. M. Mrozik, O. W. Blaschuk, C. M. Cheong, A. C. Zannettino, and K. Vandyke, N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer, BMC Cancer, vol.18, p.939, 2018.

J. Nam, M. Kang, A. M. Suchar, T. Shimamura, E. A. Kohn et al., Chemokine (C-C Motif) Ligand 2 Mediates the Prometastatic Effect of Dysadherin in Human Breast Cancer Cells, Cancer Res, vol.66, pp.7176-7184, 2006.

Y. Jia, H. Shi, Y. Cao, W. Feng, M. Li et al., PDZ and LIM domain protein 4 suppresses the growth and invasion of ovarian cancer cells via inactivation of STAT3 signaling, Life Sci, vol.233, 2019.

M. G. Donovan, O. I. Selmin, T. C. Doetschman, and D. F. Romagnolo, Epigenetic Activation of BRCA1 by Genistein In Vivo and Triple Negative Breast Cancer Cells Linked to Antagonism toward Aryl Hydrocarbon Receptor, Nutrients, vol.11, 2019.

P. S. Campbell, N. Mavingire, S. Khan, L. K. Rowland, J. V. Wooten et al., AhR ligand Aminoflavone suppresses ?6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells, J. Cell. Physiol, vol.234, pp.108-121, 2018.

E. F. O'donnell, D. C. Koch, W. H. Bisson, H. S. Jang, and S. K. Kolluri, The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells, Cell Death Dis, vol.5, 1038.

A. Pillon, A. Boussioux, A. Escande, S. Aït-aïssa, E. Gomez et al., Binding of Estrogenic Compounds to Recombinant Estrogen Receptor-?: Application to Environmental Analysis, Environ. Health Perspect, vol.113, pp.278-284, 2005.
URL : https://hal.archives-ouvertes.fr/hal-00187720

H. Satsu, K. Yoshida, A. Mikubo, H. Ogiwara, T. Inakuma et al., Establishment of a stable aryl hydrocarbon receptor-responsive HepG2 cell line, Cytotechnology, vol.67, pp.621-632, 2015.

J. B. Powell, G. D. Goode, and S. E. Eltom, The Aryl Hydrocarbon Receptor: A Target for Breast Cancer Therapy, J. Cancer Ther, vol.4, pp.1177-1186, 2013.

A. Jitariu, A. M. Cîmpean, D. Ribatti, and M. Raica, Triple negative breast cancer: The kiss of death, Oncotarget, vol.8, pp.46652-46662, 2017.

S. Vacher, P. Castagnet, W. Chemlali, F. Lallemand, D. Meseure et al., Perrot-Applanat, M. High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism, PLoS ONE, vol.13, 2018.

M. Mescher and T. Haarmann-stemmann, Modulation of CYP1A1 metabolism: From adverse health effects to chemoprevention and therapeutic options, Pharmacol. Ther, vol.187, pp.71-87, 2018.

A. Kasai, N. Hiramatsu, K. Hayakawa, J. Yao, and M. Kitamura, Blockade of the Dioxin Pathway by Herbal Medicine Formula Bupleuri Minor: Identification of Active Entities for Suppression of AhR Activation, Biol. Pharm. Bull, vol.31, pp.838-846, 2008.

, Int. J. Mol. Sci, vol.2020, p.1368

R. F. Casper, M. Quesne, I. M. Rogers, T. Shirota, A. Jolivet et al., Resveratrol Has Antagonist Activity on the Aryl Hydrocarbon Receptor: Implications for Prevention of Dioxin Toxicity, vol.56, pp.784-790, 1999.

X. Guan, Cancer metastases: Challenges and opportunities, Acta Pharm. Sin. B, vol.5, pp.402-418, 2015.

P. P. Carriere, S. D. Llopis, A. C. Naiki, G. Nguyen, T. Phan et al., Glyceollin I Reverses Epithelial to Mesenchymal Transition in Letrozole Resistant Breast Cancer through ZEB1, Int. J. Environ. Res. Public Health, vol.13, 2016.

H. J. Kim, B. Cha, B. Choi, J. S. Lim, J. Woo et al., Glyceollins inhibit platelet-derived growth factor-mediated human arterial smooth muscle cell proliferation and migration, Br. J. Nutr, vol.107, pp.24-35, 2012.

M. Källberg, H. Wang, S. Wang, J. Peng, Z. Wang et al., Template-based protein structure modeling using the RaptorX web server, Nat. Protoc, vol.7, pp.1511-1522, 2012.

E. Chovancova, A. Pavelka, P. Benes, O. Strnad, J. Brezovsky et al., CAVER 3.0: A Tool for the Analysis of Transport Pathways in Dynamic Protein Structures, PLoS Comput. Biol, vol.8, 2012.

M. L. Connolly, Analytical molecular surface calculation, J. Appl. Crystallogr, vol.16, pp.548-558, 1983.

O. Korb, T. Stützle, and T. E. Exner, Empirical scoring functions for advanced protein-ligand docking with PLANTS, J. Chem. Inf. Model, vol.49, pp.84-96, 2009.

M. Soumillon, D. Cacchiarelli, S. Semrau, A. Van-oudenaarden, and T. S. Mikkelsen, Characterization of directed differentiation by high-throughput single-cell RNA-Seq, 2014.

F. Chalmel and M. Primig, The Annotation, Mapping, Expression and Network (AMEN) suite of tools for molecular systems biology, BMC Bioinform, vol.9, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00521445

G. K. Smyth, Linear models and empirical bayes methods for assessing differential expression in microarray experiments, Stat. Appl. Genet. Mol. Biol, vol.3, issue.3, 2004.